Correlation between CpG methylation profiles and hormone receptor status in breast cancers

被引:114
作者
Feng, Weiwei
Shen, Lanlan
Wen, Sijin
Rosen, Daniel G.
Jelinek, Jaroslav
Hu, Xin
Huan, Shaoyi
Huang, Miao
Liu, Jinsong
Sahin, Aysegul A.
Hunt, Kelly K.
Bast, Robert C., Jr.
Shen, Yu
Issa, Jean-Pierre J.
Yu, Yinhua
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
关键词
D O I
10.1186/bcr1762
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Aberrant DNA methylation has been found frequently in human breast cancers, associated with the loss of expression of a number of regulatory genes for growth and correlated to clinical outcomes. The present study was undertaken to determine whether methylation of a set of growth-suppressor genes would correlate to the expression of estrogen receptors ( ERs) and progesterone receptors (PRs). Methods We used a pyrosequencing methylation analysis to study the methylation of 12 known growth-suppressor genes in 90 pairs of malignant/normal breast tissues. We also examined the expression of ERs and PRs in those specimens by immunohistochemistry. Mutations of p53 in tumor cells were detected by direct sequencing. Results Twelve tumor-suppressor genes: ARHI, RASSF1A, HIN-1, RAR beta 2, hMLH1, 14-3-3 sigma, RIZ1, p16, E- cadherin, RIL, CDH13, and NKD2 were selected for this methylation study. Five of them ( RIL, HIN- 1, RASSF1A, CDH13, and RAR beta 2) were frequently methylated in breast cancers ( 57%, 49%, 58%, 44%, and 17%, respectively) but not the normal breast ( 0-4%). Two panels of methylation profiles were defined. The methylation of the HIN-1/RASSFIA panel strongly correlated to the expression of ERs, PRs, and hormone receptors ( HRs; which were defined as ' positive' if ERs and/or PRs were positive; p < 0.001). Conversely, the methylation of the RIL/CDH13 panel strongly correlated to negative ER, PR, and HR expression ( p = 0.001, 0.025, and 0.001, respectively). The subset of triple-negative breast cancers ( in other words, those with negative ER, PR, and HER-2/neu status) was positively associated with the methylation of the RIL/CDH13 panel and negatively associated with the HIN-1/RASSF1A panel. Mutations of p53 were found in nine breast tumors ( 11%), seven of which lacked methylation in both panels. Conclusion We have defined two panels ( HIN-1/RASSFIA, and RIL/CDH13) of methylation profiles, which correlated, either positively or negatively, to HR status.
引用
收藏
页数:13
相关论文
共 39 条
  • [11] DNA methylation of RASSF1A, Hin-1, RAR-β, cyclin D2 and twist in in situ and invasive lobular breast carcinoma
    Fackler, MJ
    McVeigh, M
    Evron, E
    Garrett, E
    Mehrotra, J
    Polyak, K
    Sukumar, S
    Argani, P
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (06) : 970 - 975
  • [12] Mutational spectrum of p53 mutations in primary breast and ovarian tumors
    Feki, A
    Irminger-Finger, I
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 52 (02) : 103 - 116
  • [13] High frequency of hypermethylation at the 14-3-3 σ locus leads to gene silencing in breast cancer
    Ferguson, AT
    Evron, E
    Umbricht, CB
    Pandita, TK
    Chan, TA
    Hermeking, H
    Marks, JR
    Lambers, AR
    Futreal, PA
    Stampfer, MR
    Sukumar, S
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (11) : 6049 - 6054
  • [14] Breast cancer DNA methylation profiles in cancer cells and tumor stroma:: Association with HER-2/neu status in primary breast cancer
    Fiegl, H
    Millinger, S
    Goebel, G
    Müller-Holzner, E
    Marth, C
    Laird, PW
    Widschwendter, M
    [J]. CANCER RESEARCH, 2006, 66 (01) : 29 - 33
  • [15] Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation
    Fujii, S
    Luo, RZ
    Yuan, JH
    Kadota, M
    Oshimura, M
    Dent, SR
    Kondo, Y
    Issa, JPJ
    Bast, RC
    Yu, YH
    [J]. HUMAN MOLECULAR GENETICS, 2003, 12 (15) : 1791 - 1800
  • [16] E-cadherin promoter methylation can regulate its expression in invasive ductal breast cancer tissue in Chinese woman
    Hu, XC
    Loo, WTY
    Chow, LWC
    [J]. LIFE SCIENCES, 2002, 71 (12) : 1397 - 1404
  • [17] Issa JPJ, 2003, CLIN CANCER RES, V9, P2879
  • [18] Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate
    Issa, JPJ
    Gharibyan, V
    Cortes, J
    Jelinek, J
    Morris, G
    Verstovsek, S
    Talpaz, M
    Garcia-Manero, G
    Kantarjian, HM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) : 3948 - 3956
  • [19] PTEN promoter is methylated in a proportion of invasive breast cancers
    Khan, S
    Kumagai, T
    Vora, J
    Bose, N
    Sehgal, I
    Koeffler, PH
    Bose, S
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (03) : 407 - 410
  • [20] Krop I, 2003, CANCER RES, V63, P2024